10/22/2024 | Press release | Distributed by Public on 10/22/2024 18:31
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|
||||||||||||||||||||||||||||
|
1. Title of Derivate Security | 2. Date Exercisable and Expiration Date | 3. Title and Amount of Securities Underlying Derivative Security | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) | 6. Nature of Indirect Beneficial Ownership |
Date Exercisable | Expriation Date | Title | Amount or Number of Shares |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
Knight Therapeutics Inc 3400 DE MAISONNEUVE W. SUITE 1055 MONTREAL, A8H3Z 3B8 |
|
X |
|
|
KNIGHT THERAPEUTICS INTERNATIONAL SA DR LUIS BONAVITA 1294 OF. 2004 MONTEVIDEO, X311300 |
|
X |
|
|
KNIGHT THERAPEUTICS INC. By: /s/ Samira Sakhia, President and Chief Executive Officer | 2024-10-22 |
**Signature of Reporting Person | Date |
KNIGHT THERAPEUTICS INTERNATIONAL S.A. By: /s/ Arvind Utchanah, President of the Board of Directors | 2024-10-22 |
**Signature of Reporting Person | Date |
(*) | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
(**) | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |